Literature DB >> 30398703

Highly Efficient In Vivo Targeting of the Pulmonary Endothelium Using Novel Modifications of Polyethylenimine: An Importance of Charge.

Andrew W Dunn1, Vladimir V Kalinichenko2, Donglu Shi1.   

Abstract

Pulmonary vascular disease encompasses a wide range of serious afflictions with important clinical implications. There is critical need for the development of efficient, nonviral gene therapy delivery systems. Here, a promising avenue to overcome critical issues in efficient cell targeting within the lung via a uniquely designed nanosystem is reported. Polyplexes are created by functionalizing hyperbranched polyethylenimine (PEI) with biological fatty acids and carboxylate-terminated poly(ethylene glycol) (PEG) through a one-pot 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride/N-hydroxysuccinimide reaction. Following intravenous injection, polyplexes show an exceptionally high specificity to the pulmonary microvascular endothelium, allowing for the successful delivery of stabilized enhanced green fluorescent protein (eGFP) expressing messenger ribonucleic acid (mRNA). It is further shown, quantitatively, that positive surface charge is the main mechanism behind such high targeting efficiency for these polyplexes. Live in vivo imaging, flow cytometry of single cell suspensions, and confocal microscopy are used to demonstrate that positive polyplexes are enriched in the lung tissue and disseminated in 85-90% of the alveolar capillary endothelium, whilst being sparse in large vessels. Charge modification, achieved through poly(acrylic acid) or heparin coating, drives a highly significant reduction in both targeting percentage and targeting strength, highlighting the importance of specific surface charge, derived from chemical formulation, for efficient targeting of the pulmonary microvascular endothelium.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  in vivo targeting; nanotechnology; polymer science

Mesh:

Substances:

Year:  2018        PMID: 30398703     DOI: 10.1002/adhm.201800876

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  18 in total

1.  The S52F FOXF1 Mutation Inhibits STAT3 Signaling and Causes Alveolar Capillary Dysplasia.

Authors:  Arun Pradhan; Andrew Dunn; Vladimir Ustiyan; Craig Bolte; Guolun Wang; Jeffrey A Whitsett; Yufang Zhang; Alexey Porollo; Yueh-Chiang Hu; Rui Xiao; Przemyslaw Szafranski; Donglu Shi; Pawel Stankiewicz; Tanya V Kalin; Vladimir V Kalinichenko
Journal:  Am J Respir Crit Care Med       Date:  2019-10-15       Impact factor: 21.405

2.  Nanoparticle-Facilitated Gene Delivery in Congenital Pulmonary Vascular Disease: Roadmap for Other Forms of Pulmonary Hypertension.

Authors:  Jane A Leopold
Journal:  Circulation       Date:  2021-08-16       Impact factor: 39.918

3.  Genome Editing for Rare Diseases.

Authors:  Arun Pradhan; Tanya V Kalin; Vladimir V Kalinichenko
Journal:  Curr Stem Cell Rep       Date:  2020-07-07

Review 4.  Delivery of transcription factors as modulators of cell differentiation.

Authors:  Héctor Rilo-Alvarez; Adriana M Ledo; Anxo Vidal; Marcos Garcia-Fuentes
Journal:  Drug Deliv Transl Res       Date:  2021-02-20       Impact factor: 4.617

5.  Nanoparticle Delivery of Proangiogenic Transcription Factors into the Neonatal Circulation Inhibits Alveolar Simplification Caused by Hyperoxia.

Authors:  Craig Bolte; Vladimir Ustiyan; Xiaomeng Ren; Andrew W Dunn; Arun Pradhan; Guolun Wang; Olena A Kolesnichenko; Zicheng Deng; Yufang Zhang; Donglu Shi; James M Greenberg; Alan H Jobe; Tanya V Kalin; Vladimir V Kalinichenko
Journal:  Am J Respir Crit Care Med       Date:  2020-07-01       Impact factor: 21.405

Review 6.  Therapeutic Potential of Endothelial Progenitor Cells in Pulmonary Diseases.

Authors:  Olena A Kolesnichenko; Jeffrey A Whitsett; Tanya V Kalin; Vladimir V Kalinichenko
Journal:  Am J Respir Cell Mol Biol       Date:  2021-11       Impact factor: 6.914

Review 7.  Nanoparticle Delivery Systems with Cell-Specific Targeting for Pulmonary Diseases.

Authors:  Zicheng Deng; Gregory T Kalin; Donglu Shi; Vladimir V Kalinichenko
Journal:  Am J Respir Cell Mol Biol       Date:  2021-03       Impact factor: 6.914

Review 8.  Synthetic modified messenger RNA for therapeutic applications.

Authors:  Minsong Gao; Qingyi Zhang; Xin-Hua Feng; Jianzhao Liu
Journal:  Acta Biomater       Date:  2021-06-13       Impact factor: 8.947

Review 9.  From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

10.  Nanoparticle Delivery of STAT3 Alleviates Pulmonary Hypertension in a Mouse Model of Alveolar Capillary Dysplasia.

Authors:  Fei Sun; Guolun Wang; Arun Pradhan; Kui Xu; Jose Gomez-Arroyo; Yufang Zhang; Gregory T Kalin; Zicheng Deng; Ronald J Vagnozzi; Hua He; Andrew W Dunn; Yuhua Wang; Allen J York; Rashmi S Hegde; Jason C Woods; Tanya V Kalin; Jeffery D Molkentin; Vladimir V Kalinichenko
Journal:  Circulation       Date:  2021-06-11       Impact factor: 39.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.